SEC Form 4 research
| Issuer | Cyclerion Therapeutics, Inc. |
|---|---|
| Tickers | CYCN, KRSA |
| Reporting owners | 37 |
| Officers and directors | 6 |
| Last public filing | 2026-09-10 |
| Available | Trade date | Reporting owners | Code | Shares | Price | Reported value |
|---|---|---|---|---|---|---|
| 2026-09-10 | 2026-09-09 | Pernice Michelle Patricia | A | 48,445 | $0 | Not reported |
| 2026-09-10 | 2026-09-09 | Shah Nimish P | A | 48,445 | $0 | Not reported |
| 2026-09-10 | 2026-09-09 | Fairmount Funds Management LLC, Fairmount Healthcare Co-Invest VI L.P., Fairmount Healthcare Fund II L.P., Harwin Peter Evan, Kiselak Tomas | A | 48,445 | $0 | Not reported |
| 2026-09-10 | 2026-09-09 | Gottesdiener Andrew | A | 48,445 | $0 | Not reported |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.